copaydosingefficacyresourcesafety

THIS SITE IS INTENDED FOR US AUDIENCES ONLY

Moderate to Severe Plaque Psoriasis

Start your patients on Otezla
DISCOVER RESULTS IN
Plaque Psoriasis*†

Download START form
Adult woman sitting in a chair speaking to 4 children sitting on the floor

Resource Center

Download a Letter of Medical Necessity, patient support tools, and more

Explore resources

Proven Efficacy1-3

Results from clinical trials evaluating the clinical efficacy of Otezla® (apremilast)

Learn more

Safety

Learn more about the safety results reported in Otezla clinical trials

Learn more

Dosing

Otezla is an oral, non‑biologic therapy1,2

Learn more

  $0 Co-pay†*

Otezla is available to most commercially insured patients for $0

Learn more

Download the Start Form
*†The efficacy and safety of Otezla was evaluated in 2 multicenter, double-blind, placebo-controlled trials of similar design. Patients with moderate to severe plaque psoriasis (N = 1257) were randomized 2:1 to Otezla 30 mg twice daily or placebo for 16 weeks after a 5-day titration.1,3,4 In ESTEEM 1, Otezla significantly increased PASI-75 response (n = 562) at week 16 (primary endpoint) vs placebo (n = 282) (33% vs 5%; P < 0.0001).1,3

The most common adverse reactions (≥5%) were diarrhea, nausea, upper respiratory tract infection, tension headache, and headache.1
†*

Certain restrictions apply; eligibility not based on income, must be 18 years or older. This offer is not valid for persons eligible for reimbursement of this product, in whole or in part under Medicaid, Medicare, or similar state or federal programs. Offer not valid for cash-paying patients. People who are not eligible can call 1-844-4OTEZLA to discuss other financial assistance opportunities.

ESTEEM, Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; PASI, Psoriasis Area and Severity Index.

References: 1. Otezla [package insert]. Thousand Oaks, CA: Amgen Inc. 2. Data on file, Amgen Inc. 3. Papp K, Reich K, Leonardi CL, et al. J Am Acad Dermatol. 2015;73(1):37-49. 4. Paul C, Cather J, Gooderham M, et al. Br J Dermatol. 2015;173(6):1387-1399.

Indications & Important Safety Information

Please click here for Full Prescribing Information.

You are leaving the Otezla® (apremilast) website

Do you wish to leave this site?

Are You a Healthcare Professional?

.marketAccessModal .lineOne, .marketAccessModal .lineTwo { font-size: 44px; text-transform: none; margin-bottom: 10px; } .marketAccessModal .lineTwo { font-size: 42px; text-transform: none; } @media screen and (max-width: 450px) { .marketAccessModal .lineOne, .marketAccessModal .lineTwo { font-size: calc(15px + 7 * ((100vw - 325px) / 125)); } }
The FDA approves a new indication for Otezla® (apremilast) Learn more about this treatment option for your patients
EXPLORE